💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Incyte Corporation (INCY)
« Back to company indexINCY Chatter Timeline
Stock Ticker for INCY
Most Active Tweeters for INCY
| User | Tweets |
|---|---|
| @Tickeron | 14 |
| @mediasentiment | 5 |
| @sleekoptions | 4 |
| @newsfilterio | 3 |
| @DataTrials | 3 |
Recent Tweets for INCY
 |
@newsfilterio Incyte Ranked Second Among Science Magazine’s 2020 Top Biopharma Employers $INCY https://t.co/8CQ4nRyGHo October 30th 2020, 1:10pm |
 |
@tradersreport RT @Tickeron: $INCY's Aroon indicator drops into Downtrend on October 5, 2020. View odds for this and other indicators: https://t.co/NNVZyW… October 30th 2020, 10:10am |
 |
@Tickeron $INCY's Aroon indicator drops into Downtrend on October 5, 2020. View odds for this and other indicators:… https://t.co/OBkaVeJk2K October 30th 2020, 10:10am |
 |
@FlashAlert_me $INCY [15s. delayed]: Issued Press Release on October 30, 09:00:00: Incyte Ranked Second Among Science Magazine’s 2… https://t.co/lsvkv0oILT October 30th 2020, 9:10am |
 |
@stock_titan $INCY Incyte Ranked Second Among Science Magazine’s 2020 Top Biopharma Employers https://t.co/YkTWinOAJI October 30th 2020, 9:10am |
 |
@MarcJacksonLA $LLY $INCY Lilly & Incyte Report Positive New Data For Baricitinib In Adult Patients With Alopecia https://t.co/OY6ySIkFWT October 30th 2020, 8:10am |
 |
@equity_newswire $INCY Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinic… https://t.co/EphVygBWbD October 30th 2020, 7:10am |
 |
@sbwcws Eli Lilly, Incyte announce to present new baricitinib data $LLY $INCY October 30th 2020, 6:10am |
|
@stock_titan $INCY $LLY Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Pat… https://t.co/VMyxZ45gw1 October 30th 2020, 6:10am |
 |
@Miljenkoz RT @Mazeraski: $INCY Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported QoL Assessm… October 29th 2020, 10:10am |
 |
@Briefingcom $INCY: Incyte announced efficacy and safety results from a pooled analysis of two randomized, double-blind,... https://t.co/MzmSKPJBjp October 29th 2020, 10:10am |
|
@Tickeron $INCY's Aroon indicator drops into Downtrend on October 5, 2020. View odds for this and other indicators:… https://t.co/RyGgAbmnOn October 29th 2020, 9:10am |
|
@MarcJacksonLA $INCY Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinic… https://t.co/PuIQv0K2VJ October 29th 2020, 9:10am |
 |
@Mazeraski $INCY Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Qo… https://t.co/I0dPvnpPoZ October 29th 2020, 9:10am |
|
@sbwcws Incyte announces pooled analysis evaluating ruxolitinib cream for dermatitis $INCY October 29th 2020, 8:10am |
 |
@the_pnw_yeti $incy some relative strength October 28th 2020, 3:10pm |
|
@Tickeron $INCY's Aroon indicator drops into Downtrend on October 5, 2020. View odds for this and other indicators:… https://t.co/ksiIxOfBzN October 28th 2020, 9:10am |
 |
@TradHawk RT @TradeHawk: $INCY Incyte has been awarded a five year Veterans Affairs federal supply schedule contract worth $541 million. https://t.c… October 27th 2020, 1:10pm |
 |
@DataTrials $INCY Phase 1|Phase 2 Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer…NCT0206… https://t.co/S7eRxfMhsC October 27th 2020, 11:10am |
|
@DataTrials $INCY Phase 3 Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Sa… https://t.co/yLaj8fbEyr October 27th 2020, 11:10am |
|
@DataTrials $INCY Phase 2 Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Ch… https://t.co/AwvuihHSf9 October 27th 2020, 11:10am |
|
@Tickeron $INCY's Aroon indicator drops into Downtrend on October 5, 2020. View odds for this and other indicators:… https://t.co/qt6kJMlO18 October 27th 2020, 9:10am |
 |
@quant_data Incyte Received FDA Orphan Drug Designation for Retifanlimab for Treatment of Merkel Cell Carcinomaon October 26 Related Tickers: $INCY October 27th 2020, 6:10am |
 |
@s949kYPg5RyIwHm RT @G_krupins: $INCY If it holds here and resumes it's move up https://t.co/7AuDB0tBQ6 October 26th 2020, 7:10pm |
 |
@UnusuallyActive INCYTE CORPORATION $INCY UNUSUAL ACTIVITY VOLUME 2628.51% STRENGTH 3669.33% October 26th 2020, 10:10am |
|
@newsfilterio Health Canada accepts Incyte's pemigatinib application for bile duct cancer $INCY https://t.co/e973kyac5u October 26th 2020, 10:10am |
 |
@HealthcareBeat Health Canada accepts Incyte's pemigatinib application for bile duct cancer $INCY https://t.co/pxwK4h7TJD October 26th 2020, 10:10am |
|
@Tickeron $INCY enters a Downtrend as Momentum Indicator dropped below the 0 level on October 21, 2020. View odds for this an… https://t.co/ZTZ8qfgLHS October 26th 2020, 8:10am |
|
@Tickeron $INCY enters a Downtrend because Momentum Indicator dropped below the 0 level on October 21, 2020. View odds for th… https://t.co/wIZQtB1Jul October 25th 2020, 9:10am |
|
@Tickeron $INCY enters a Downtrend as Momentum Indicator dropped below the 0 level on October 21, 2020. View odds for this an… https://t.co/Gb0oeYs6ip October 24th 2020, 9:10am |
 |
@optioncharts $INCY Implied Volatility expiration 11/20/2020 #maxpain #options https://t.co/sH1sMMu31D https://t.co/CeAs835ZTJ October 23rd 2020, 8:10pm |
|
@Tickeron $INCY's Aroon indicator drops into Downtrend on October 5, 2020. View odds for this and other indicators:… https://t.co/3xCutU6d0q October 23rd 2020, 11:10am |
 |
@sleekoptions Peak profit for the last 6 expired option alerts for $INCY 128.57% | 136.00% | -97.08% | 6.25% | 3.02% | 19.27% |… https://t.co/4lmb1qULKC October 22nd 2020, 7:10pm |
|
@sleekoptions $INCY - #OptionsTrading - Monthly performance of the algo based option alerts posted for INCY https://t.co/mncZfr5jCN October 22nd 2020, 7:10pm |
|
@sleekoptions $INCY - Last six months, 22 option alerts peaked above 100% after they were triggered by the algo… https://t.co/lZ86c3fvHl October 22nd 2020, 7:10pm |
|
@sleekoptions $INCY - View historical options performance for INCY https://t.co/fBAay8o89T https://t.co/j0Fu91dkPR October 22nd 2020, 7:10pm |
|
@Tickeron $INCY's Aroon indicator drops into Downtrend on October 5, 2020. View odds for this and other indicators:… https://t.co/dMQ8aTzOEJ October 22nd 2020, 9:10am |
 |
@OlympiaReport Incyte Co. $INCY Receives Average Rating of “Hold” from Brokerages https://t.co/mTuAcdo7b3 October 21st 2020, 6:10pm |
|
@Tickeron $INCY's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram just turned negative. View odds for th… https://t.co/B7w9G0uTYh October 21st 2020, 11:10am |
|
@HealthcareBeat Incyte to Report Third Quarter Financial Results $INCY https://t.co/4sokUneSNW October 21st 2020, 5:10am |
|
@newsfilterio Incyte to Report Third Quarter Financial Results $INCY https://t.co/Qn0QQA4jt5 October 21st 2020, 2:10am |
 |
@ThisLincolnian Incyte Co. $INCY Expected to Post Earnings of $0.72 Per Share https://t.co/BMldaMVn3R October 21st 2020, 1:10am |
 |
@dailypoliticaln Incyte Co. $INCY Expected to Post Earnings of $0.72 Per Share https://t.co/zxQUYgY85t October 21st 2020, 1:10am |
 |
@WatchlistN $0.72 EPS Expected for Incyte Co. $INCY This Quarter https://t.co/NujyY8uekp October 21st 2020, 1:10am |
 |
@AmericanBanking Incyte Co. $INCY Expected to Post Earnings of $0.72 Per Share https://t.co/T5xuGyaxto #stocks October 21st 2020, 1:10am |
 |
@76enz $INCY 6% October 20th 2020, 10:10am |
|
@Tickeron $INCY's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram crosses below signal line. View odds f… https://t.co/3qmp2F4Qzp October 20th 2020, 8:10am |
|
@FlashAlert_me $INCY [15s. delayed]: Issued Press Release on October 20, 08:00:00: Incyte to Report Third Quarter Financial Results https://t.co/JMKqDXDAQQ October 20th 2020, 8:10am |
|
@stock_titan $INCY Incyte to Report Third Quarter Financial Results https://t.co/Nzf0vLFRtK October 20th 2020, 8:10am |
|
@dakotafinancial Reviewing Incyte $INCY & Inhibitor Therapeutics $INTI https://t.co/rqaqrZSM9t October 20th 2020, 7:10am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2020. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
- ✓ Patent Expirations and Generic Entry
- ✓ 505(b)(2) & Biosimilars
- ✓ Insightful Articles and Case Studies
- ✓ Patent Litigation & Challenges
- ✓ Industry Trends
